As previously mentioned, luteolin also shows promising effects by significantly alleviating DSS-induced colitis in mice by reducing HMGB1 mRNA and protein levels and downregulating the HMGB1-TLR-NF-κB signaling pathway. Here, HMGB1 is linked to colitis.